Nanofluidic membrane
Precisely engineered nanochannels enable constant, zero-order drug release without burst effects.
A refillable nanofluidic implant for ultra-long-acting, zero-order drug release
NanoDDI is a subcutaneous refillable implant designed to maintain constant zero-order drug delivery for years. Unlike traditional dosing or long-acting systems that suffer from peaks and troughs, burst release, declining rates, or low drug loading, NanoDDI providing long-term stable therapeutic release. Validated by decades of safety and usability research (see Publications), the NanoDDI is available through the DART Program to support preclinical HIV studies requiring consistent antiretroviral dosing.
Key features
High-capacity drug loading
Solid drug loading enables higher density and long-term stability within the implant.
Tunable release rate
Nanochannel geometry and density can be tuned to match required daily dosing.
Customizable reservoir
A titanium reservoir can be tailored to the target drug load and duration of delivery—supporting small form factors for high-potency drugs or larger volumes for higher-dose/combination therapies.
Minimally invasive implantation
Inserted just beneath the skin via a brief procedure. No pumps, batteries, or external hardware.
Transcutaneous refillability
Two embedded silicone ports allow refilling through the skin using only two syringes.
How it works
Workflow
1
Implantation
Subcutaneous insertion via a brief, minimally invasive procedure.
2
Solid drug loading
Drug microparticles are injected through the refill port; the titanium filter retains solids.
3
Zero-order release
Interstitial fluid enters, dissolves drug, and molecules diffuse through nanochannels at constant flux.
4
Transcutaneous refilling (optional)
When needed, the device is refilled through the skin to extend release.
5
Removal
Rapid, minimally invasive removal when required.
How refilling works
- A syringe injects a drug suspension through the loading port.
- An internal titanium micro-filter retains solid drug particles.
- Excess fluid exits through the venting port.
- Silicone ports reseal immediately after needle withdrawal.
Performance
Duration
Multi-Year
Constant drug release without refilling.
Safety
Biocompatible & Tolerable
Demonstrated biocompatibility without any local or systemic adverse effects.
Durability
Implant patency
No biofouling or occlusion. Release unaffected by fibrotic capsule formation.